Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone; Doxorubicin liposomal
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen; Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 21 Sep 2020 Results of subanalysis presented at the 45th European Society for Medical Oncology Congress
    • 14 Sep 2020 According to a PharmaMar media release, subanalysis of this trial will be presented at the European Society of Medical Oncology (ESMO) Congress, which will be held virtually from 17th to 19th of Sep 2020.
    • 24 Jul 2020 According to an European Medicines Agency media release, EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of this study.However, the study results will be included in the medicine product information to provide healthcare professionals with the most up-to-date information on the effects of Yondelis in patients with ovarian cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top